We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3,866.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
25/5/2023 11:51 | Purchased CFDs....looks like a bit of a punt by the KIO. | steeplejack | |
25/5/2023 11:28 | looks like Kuwait investment fund bought 1% 3 days ago at 3167 | tonysss13 | |
22/5/2023 15:32 | Yes,the management won’t be that keen if EQT try to bid them down due to destocking which could well prove to be but a temporary interruption to growth.Thereagain,Co | steeplejack | |
22/5/2023 15:17 | BOD will find it v hard to deal below £40 Pipeline reduction doesn’t last that long | phillis | |
22/5/2023 08:01 | Chances of a bid at £40 now receding, unless EQT and management see this as a temporary trading event. If they do progress at that level, they can be confident of getting the deal done, unlike Apollo who could not convince Wood of the value of their bid. It would not be surprising to see the bid fall to £38 or so…which is still a decent premium. £35 is going to be difficult for the Board to recommend, but if there is no bid then these will be £25. | 1jat | |
22/5/2023 07:51 | There have been too many failed bids recently, just last week Apollo walked away from Wood Group. I guess the question is would the board recommend a bid around the £35 level and would the major shareholders support it? | salpara111 | |
22/5/2023 07:13 | So will EQT adjust its offer to reflect the tough trading conditions currently being encountered.The current price sits near halfway between the price before the bid emerged ie around £26 and the value of the cash bid of a tad over £40.I presume we'll know whether a bid will emerge by June 2,you can't keep kicking the can down the road. | steeplejack | |
10/5/2023 08:44 | Yes an extension is quite likely if discussions are ongoing. | steeplejack | |
10/5/2023 08:31 | Am not up to date with the rules DPH could agree to an extension I think | phillis | |
09/5/2023 20:09 | Slight decline suggests some uncertainty about EQT bid emerging…..cer Of course there could be an extension on Thursday | 1jat | |
09/5/2023 11:05 | EQT has until 11th May ie Thursday to make a firm offer. | steeplejack | |
14/4/2023 08:04 | EQT’s involvement with IVC (UK’s biggest vet consolidator) could cause some issues for them? | spyder | |
14/4/2023 07:39 | The shares traded well over £50 eighteen months ago.All decent mid sized UK companies get snapped up over time. | steeplejack | |
13/4/2023 16:42 | 4070p bid not to bad. | montyhedge | |
28/2/2023 10:29 | Analysts at Jefferies said they expected full-year operating profit to be about £188 million, versus £191 million previously. | steeplejack | |
27/2/2023 16:51 | That's the problem with very high p.e companies. If they hit a bump in the road they get hammered. | montyhedge | |
27/2/2023 15:36 | Indeed.I contemplated selling a few but i like the area in which this group operates.Veterniary products command excellent margins. I suppose a good few 'pandemic purchasing'dog owners are discovering that canines are more needy than stuffed toys but the investment case for holding a global company in this industry remains pretty compelling. | steeplejack | |
27/2/2023 13:55 | Well, it has recovered half this morning's loss now. | vulgaris | |
27/2/2023 10:00 | Trading patterns at the start of 2023 have been unpredictable in the US, where wholesalers have been reducing inventory levels. In the second half, we have re-commenced sales in South Korea, we expect an improving contribution from Med-Pharmex and will see the benefit of two recent new product launches, Zenalpha and Zycosan. Based on the recent US de-stocking and current exchange rates, the Board now expects full year underlying operating profit to be at the lower end of analyst expectations.This type of result could be the sort of reality check that moderates investor enthusiasm for equities in general in 2023. | steeplejack | |
27/2/2023 09:27 | I'll give it a year or two and look again . | johnrxx99 | |
27/2/2023 08:52 | Mr Page is always self congratulatory but these results seem at variance with the pretty upbeat trading update in January.The operating profit is a big miss on consensus forecasts and note that the flagship US market is expected to come in at the low end of estimates now.There are obvious explanations,acquisi | steeplejack | |
27/2/2023 08:34 | I think the share price agrees with you | prokartace | |
27/2/2023 07:20 | The 6 month results look nasty. What do you think? | johnrxx99 | |
02/2/2023 08:23 | Back through £30 to a three month high.Life in the old dog yet as no doubt they say in Dechra research laboratories. | steeplejack |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions